Compare TPVG & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPVG | SWKH |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Diversified Financial Services |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.8M | 205.9M |
| IPO Year | N/A | 1999 |
| Metric | TPVG | SWKH |
|---|---|---|
| Price | $5.74 | $17.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $6.38 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 337.0K | 7.1K |
| Earning Date | 03-04-2026 | 03-18-2026 |
| Dividend Yield | ★ 15.62% | N/A |
| EPS Growth | ★ 208.85 | 120.89 |
| EPS | 0.84 | ★ 1.85 |
| Revenue | ★ $93,623,000.00 | $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | $4.92 | N/A |
| P/E Ratio | ★ $6.98 | $9.47 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $5.24 | $13.17 |
| 52 Week High | $8.20 | $20.49 |
| Indicator | TPVG | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 26.13 | 57.31 |
| Support Level | $6.25 | $17.22 |
| Resistance Level | $6.61 | $17.60 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 5.25 | 84.91 |
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.